Sanofi

(Adds strategy background in paragraph 7, Beyfortus sales in last paragraph) By Ludwig Burger April 25 (Reuters) - Sanofi's first-quarter operating income fel...

Sanofi - Aventis Groupe Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance Paris, April 25, 2024 Sales growth of 6.7% at CER...

Sanofi (NASDAQ:SNY) is reportedly lining up banks for a potential spinoff of its consumer health products division. The French drugmaker has asked banks to sub...

DelveInsight Business Research LLP The diabetes drugs market is expected to surge mainly due to factors like the growing occurrence of lifestyle-related condit...

(Bloomberg) -- French drugmaker Sanofi has asked banks to pitch for roles on the separation of its consumer-health business, according to people familiar with t...

Sanofi SNY announced positive data from the phase III LUNA 3 study, which evaluated its covalent BTK inhibitor, rilzabrutinib, for treating patients with immune...

Sanofi (NASDAQ:SNY) announced Tuesday that rilzabrutinib, an oral therapy for an autoimmune blood disorder called immune thrombocytopenia (ITP), reached the pri...

Sanofi (NASDAQ:SNY) has reportedly agreed to pay over $100M to settle around 4,000 cases filed over the safety of its heartburn drug Zantac. Under the settleme...

Sanofi will pay more than $100M to settle about 4,000 lawsuits accusing the company of failing to warn users that its Zantac heartburn medicine could cause canc...

Sanofi will pay more than $100 million to settle about 4,000 lawsuits accusing the French drugmaker of failing to warn users that its Zantac heartburn medicine...